Related Experiment Videos
Effect of simvastatin in CAPD patients with hypercholesterolemia
A De Vecchi1, A Scalamogna, M Paparella
1Divisione di Nefrologia e Dialisi, IRCCS Ospedale Magiore, Milano, Italy.
Summary
Simvastatin effectively lowers cholesterol in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). While generally safe, further research is needed on HDL cholesterol changes and clinical outcomes.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hypercholesterolemia is a common comorbidity in patients with chronic kidney disease.
- Patients on continuous ambulatory peritoneal dialysis (CAPD) often require lipid-lowering therapy.
- Statins are a primary treatment for hypercholesterolemia, but their use in CAPD patients needs specific evaluation.
Purpose of the Study:
- To investigate the efficacy and safety of simvastatin in hypercholesterolemic patients undergoing CAPD.
- To assess the impact of simvastatin on serum total cholesterol, HDL cholesterol, and triglyceride levels.
Main Methods:
- A study involving 20 hypercholesterolemic patients on CAPD treatment.
- Simvastatin dosage initiated at 10 mg/day, titrated up to 40 mg/day.
- Monitoring of serum lipid profiles and adverse events throughout the treatment period.
Main Results:
- Serum total cholesterol significantly decreased from 318 +/- 39 to 208 +/- 34 mg/dl (p < 0.001).
- Serum triglyceride levels showed a trend towards decrease (317 +/- 129 to 278 +/- 160 mg/dl).
- HDL cholesterol decreased from 43 +/- 13 to 35 +/- 11 mg/dl; simvastatin was generally well-tolerated.
Conclusions:
- Simvastatin is a safe and effective agent for lowering serum cholesterol in CAPD patients.
- The effective dosage varied among patients, with 10-40 mg/day being utilized.
- The clinical significance of simvastatin-induced HDL cholesterol reduction in this population remains to be determined.